United Therapeutics Q2 revenue misses estimates on Ebulized Tyvaso weakness

United Therapeutics

05/08/2026 11:38

Overview
Rare disease drugmaker's Q2 revenue fell 2% yr/yr, missing analyst expectations
Q2 net income rose 8% yr/yr; diluted EPS increased 13%
Revenue decline driven by lower Nebulized Tyvaso and Remodulin sales amid competition

Outlook
Company expects potential approvals for Nebulized Tyvaso in IPF and ralinepag tablets in PAH by next year
United Therapeutics plans to launch two xeno-organ production facilities later this year
Company sees continued strong demand for Tyvaso DPI, supported by device differentiation and clinical experience

Result Drivers
NEBULIZED TYVASO DECLINE - Co said Nebulized Tyvaso revenue fell due to lower U.S. quantities sold, partially offset by price increases
TYVASO DPI GROWTH - Co said Tyvaso DPI revenue rose on higher quantities sold and price increases, partially offset by higher gross-to-net deductions
COMPETITION IMPACT - Co said availability of competitive therapies negatively affected sales of Nebulized Tyvaso, Tyvaso DPI and Remodulin

Company press release: ID:nBw34Jc7Ya

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$783.30 mln
$805.65 mln (11 Analysts)
Q2 EPS
 
$7.27
 
Q2 Net Income
 
$333 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for United Therapeutics Corporation is $695.00, about 34% above its August 4 closing price of $518.68
The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 19 three months ago

Reuters Recommended Reads
Aug 4 - Ultragenyx Q2 revenue rises 28% to record high, net loss narrows
Aug 4 - Travere Therapeutics Q2 product sales rise on FILSPARI demand
Aug 3 - Krystal Biotech Q2 revenue rises on VYJUVEK strength

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)